The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Rectal Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Rectal Neoplasms


Psychiatry related information on Rectal Neoplasms


High impact information on Rectal Neoplasms

  • Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery [7].
  • Six hundred sixty patients with TNM stage II or III rectal cancer received intermittent bolus injections or protracted venous infusions of fluorouracil during postoperative radiation to the pelvis [7].
  • The combination of radiation therapy and chemotherapy with fluorouracil plus semustine after surgery has been established as an effective approach to decreasing the risk of tumor relapse and improving survival in patients with rectal cancer who are at high risk for relapse or death [7].
  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [8].
  • In conclusion, this investigation has demonstrated a benefit from adjuvant chemotherapy (MOF) for the management of rectal cancer [9].

Chemical compound and disease context of Rectal Neoplasms


Biological context of Rectal Neoplasms

  • Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer [15].
  • TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer [16].
  • Furthermore, BI-1 expression analysis using a cancer profiling array showed up-regulation of BI-1 expression in cancer samples of breast, uterus and ovary, whereas down-regulated BI-1 expression was identified in stomach, colon, kidney, lung and rectal cancer [17].
  • Five families had mutations in hMLH1, 4 of which were splice site mutations, 2 had frameshift mutations in hMSH2 and 1 patient with metachronous endometrial and rectal cancer but with a weak family history of cancer had a nonsense mutation in hMSH6 [18].
  • We analyzed the relationships of survivin expression to RT, clinicopathologic variables, apoptosis, and p53 expression in rectal cancer patients who participated in a trial of preoperative RT [19].

Anatomical context of Rectal Neoplasms

  • Treatment of the human rectal cancer cell line HRT-18 with sodium butyrate caused a reversible elevation of alkaline phosphatase activity which was inhibited by cycloheximide and actinomycin D [20].
  • FMT tumor uptake at 60 min postinjection in mice with LS180 rectal cancer, RPM11788 B-cell lymphoma and MCF7 mammary cell carcinoma was assessed, and the results were compared with 18F-fluoro-2-deoxy-D-glucose (FDG) tumor uptake [21].
  • PATIENTS AND METHODS: Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre- or postoperative radiochemotherapy: A total dose of 50.4 Gy (single dose 1.8 Gy) was applied to the tumor and the pelvic lymph nodes [22].
  • A randomised, placebo-controlled trial was conducted to study whether the subcutaneous administration of recombinant human erythropoietin (rhEPO) increases the donated red cell blood volume in patients with rectal cancer [23].
  • Twenty gastric and one rectal tumor stained diffusely with vimentin and actin, but not with desmin, and had scattered strongly S-100-positive cells that might either be trapped Schwann cells or tumor cells [24].

Gene context of Rectal Neoplasms


Analytical, diagnostic and therapeutic context of Rectal Neoplasms


  1. Diet and cancer of the colon and rectum: a case-control study. Potter, J.D., McMichael, A.J. J. Natl. Cancer Inst. (1986) [Pubmed]
  2. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Spagnesi, M.T., Tonelli, F., Dolara, P., Caderni, G., Valanzano, R., Anastasi, A., Bianchini, F. Gastroenterology (1994) [Pubmed]
  3. Presence of blood group H antigen on a carcinoembryonic antigen, and its enzymatic modification into blood group A and B specificities. Bali, J.P., Magous, R., Lecou, C., Mousseron-Canet, M. Cancer Res. (1976) [Pubmed]
  4. Mechanisms of oncogenesis in colon versus rectal cancer. Kapiteijn, E., Liefers, G.J., Los, L.C., Kranenbarg, E.K., Hermans, J., Tollenaar, R.A., Moriya, Y., van de Velde, C.J., van Krieken, J.H. J. Pathol. (2001) [Pubmed]
  5. Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. Comstock, G.W., Helzlsouer, K.J., Bush, T.L. Am. J. Clin. Nutr. (1991) [Pubmed]
  6. Comparison of risk factors for colon and rectal cancer. Wei, E.K., Giovannucci, E., Wu, K., Rosner, B., Fuchs, C.S., Willett, W.C., Colditz, G.A. Int. J. Cancer (2004) [Pubmed]
  7. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. O'Connell, M.J., Martenson, J.A., Wieand, H.S., Krook, J.E., Macdonald, J.S., Haller, D.G., Mayer, R.J., Gunderson, L.L., Rich, T.A. N. Engl. J. Med. (1994) [Pubmed]
  8. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Willett, C.G., Boucher, Y., di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T., Chung, D.C., Sahani, D.V., Kalva, S.P., Kozin, S.V., Mino, M., Cohen, K.S., Scadden, D.T., Hartford, A.C., Fischman, A.J., Clark, J.W., Ryan, D.P., Zhu, A.X., Blaszkowsky, L.S., Chen, H.X., Shellito, P.C., Lauwers, G.Y., Jain, R.K. Nat. Med. (2004) [Pubmed]
  9. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. Fisher, B., Wolmark, N., Rockette, H., Redmond, C., Deutsch, M., Wickerham, D.L., Fisher, E.R., Caplan, R., Jones, J., Lerner, H. J. Natl. Cancer Inst. (1988) [Pubmed]
  10. Enhancement of 1,2-dimethylhydrazine-induced rectal carcinogenesis following chronic ethanol consumption in the rat. Seitz, H.K., Czygan, P., Waldherr, R., Veith, S., Raedsch, R., Kässmodel, H., Kommerell, B. Gastroenterology (1984) [Pubmed]
  11. Rectal cancer in FAP patient after sulindac. Thorson, A.G., Lynch, H.T., Smyrk, T.C. Lancet (1994) [Pubmed]
  12. Possible role of acetaldehyde in ethanol-related rectal cocarcinogenesis in the rat. Seitz, H.K., Simanowski, U.A., Garzon, F.T., Rideout, J.M., Peters, T.J., Koch, A., Berger, M.R., Einecke, H., Maiwald, M. Gastroenterology (1990) [Pubmed]
  13. Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide. Jahraus, C.D., Rubin, D.T., Scherl, E.J., Bettenhausen, D. Gastroenterology (2005) [Pubmed]
  14. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. Hoff, P.M., Janjan, N., Saad, E.D., Skibber, J., Crane, C., Lassere, Y., Cleary, K.R., Benner, S., Randolph, J., Abbruzzese, J.L., Pazdur, R. J. Clin. Oncol. (2000) [Pubmed]
  15. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. Villafranca, E., Okruzhnov, Y., Dominguez, M.A., García-Foncillas, J., Azinovic, I., Martínez, E., Illarramendi, J.J., Arias, F., Martínez Monge, R., Salgado, E., Angeletti, S., Brugarolas, A. J. Clin. Oncol. (2001) [Pubmed]
  16. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Kandioler, D., Zwrtek, R., Ludwig, C., Janschek, E., Ploner, M., Hofbauer, F., Kührer, I., Kappel, S., Wrba, F., Horvath, M., Karner, J., Renner, K., Bergmann, M., Karner-Hanusch, J., Pötter, R., Jakesz, R., Teleky, B., Herbst, F. Ann. Surg. (2002) [Pubmed]
  17. Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells. Grzmil, M., Kaulfuss, S., Thelen, P., Hemmerlein, B., Schweyer, S., Obenauer, S., Kang, T.W., Burfeind, P. J. Pathol. (2006) [Pubmed]
  18. hMLH1, hMSH2 and hMSH6 mutations in hereditary non-polyposis colorectal cancer families from southern Sweden. Planck, M., Koul, A., Fernebro, E., Borg, A., Kristoffersson, U., Olsson, H., Wenngren, E., Mangell, P., Nilbert, M. Int. J. Cancer (1999) [Pubmed]
  19. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Knutsen, A., Adell, G., Sun, X.F. Int. J. Radiat. Oncol. Biol. Phys. (2004) [Pubmed]
  20. Effect of sodium butyrate on alkaline phosphatase in HRT-18, a human rectal cancer cell line. Morita, A., Tsao, D., Kim, Y.S. Cancer Res. (1982) [Pubmed]
  21. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. Inoue, T., Tomiyoshi, K., Higuichi, T., Ahmed, K., Sarwar, M., Aoyagi, K., Amano, S., Alyafei, S., Zhang, H., Endo, K. J. Nucl. Med. (1998) [Pubmed]
  22. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94). Sauer, R., Fietkau, R., Wittekind, C., Martus, P., Rödel, C., Hohenberger, W., Jatzko, G., Sabitzer, H., Karstens, J.H., Becker, H., Hess, C., Raab, R. Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]. (2001) [Pubmed]
  23. Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO). Rau, B., Schlag, P.M., Willeke, F., Herfarth, C., Stephan, P., Franke, W. Eur. J. Cancer (1998) [Pubmed]
  24. Cell markers in gastrointestinal stromal tumors. Pike, A.M., Lloyd, R.V., Appelman, H.D. Hum. Pathol. (1988) [Pubmed]
  25. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. Rau, B., Sturm, I., Lage, H., Berger, S., Schneider, U., Hauptmann, S., Wust, P., Riess, H., Schlag, P.M., Dörken, B., Daniel, P.T. J. Clin. Oncol. (2003) [Pubmed]
  26. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Palmqvist, R., Hallmans, G., Rinaldi, S., Biessy, C., Stenling, R., Riboli, E., Kaaks, R. Gut (2002) [Pubmed]
  27. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. Jakob, C., Aust, D.E., Meyer, W., Baretton, G.B., Schwabe, W., Häusler, P., Becker, H., Liersch, T. J. Pathol. (2004) [Pubmed]
  28. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. Ghadimi, B.M., Grade, M., Difilippantonio, M.J., Varma, S., Simon, R., Montagna, C., Füzesi, L., Langer, C., Becker, H., Liersch, T., Ried, T. J. Clin. Oncol. (2005) [Pubmed]
  29. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. Hoover, H.C., Brandhorst, J.S., Peters, L.C., Surdyke, M.G., Takeshita, Y., Madariaga, J., Muenz, L.R., Hanna, M.G. J. Clin. Oncol. (1993) [Pubmed]
  30. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. Johnston, P.G., Fisher, E.R., Rockette, H.E., Fisher, B., Wolmark, N., Drake, J.C., Chabner, B.A., Allegra, C.J. J. Clin. Oncol. (1994) [Pubmed]
  31. Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study. Brink, M., Weijenberg, M.P., de Goeij, A.F., Roemen, G.M., Lentjes, M.H., de Bruïne, A.P., van Engeland, M., Goldbohm, R.A., van den Brandt, P.A. Int. J. Cancer (2005) [Pubmed]
  32. An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Cascinu, S., Graziano, F., Catalano, V., Staccioli, M.P., Rossi, M.C., Baldelli, A.M., Barni, S., Brenna, A., Secondino, S., Muretto, P., Catalano, G. Br. J. Cancer (2002) [Pubmed]
WikiGenes - Universities